Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...
Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc)Core operating ...
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...
Hosted on MSN1d
Top Stock Reports for Netflix, Salesforce & CiscoHowever, the company's high debt load is a concern. Kisqali, Pluvicto Drive Novartis (NVS) Amid Competition Per the Zacks analyst, drugs like Entresto, Kesimpta, Pluvicto, Kisqali and Leqvio continue ...
In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...
Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...
Nov. 12, 2024 — The chances of intelligent life emerging in our Universe -- and in any hypothetical ones beyond it -- can be estimated by a new theoretical model ... Nov. 12, 2024 — Scientists ...
The Biden administration gave Israel 30 days to increase the flow of aid, warning that aid shipments into Gaza in September had reached an alarmingly low level. By Liam Stack and Aaron Boxerman ...
Nov. 11, 2024 — A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer ... DNA Packaging Directly Affects How Fast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback